Skip to main content
. Author manuscript; available in PMC: 2015 Jan 6.
Published in final edited form as: Arch Intern Med. 2008 Apr 14;168(7):721–727. doi: 10.1001/archinte.168.7.721

Figure 2.

Figure 2

Difference between the statin and placebo groups. A, Systolic blood pressure (SBP), change from baseline. This figure shows values for subjects who were not hypertensive at baseline, were never prescribed BP medications, and had BP measured through the 8-month visit. This mitigates the influence of changes distinct from treatment assignment across time. The change values differed significantly from placebo (P <.05) at month 6 (only) for both pravastatin sodium and simvastatin. Standard errors for pravastatin: month 1, 1.3; month 6, 1.2; month 8, 1.2. Standard errors for simvastatin: month 1, 1.2; month 6, 1.2; month 8, 1.2. P values for pravastatin: month 1, P = .18; month 6, P = .04; month 8, P = .69. P values for simvastatin: month 1, P = .30; month 6, P = .02; month 8, P = .18. B, DBP, change from baseline. This figure shows values for subjects who were not hypertensive at baseline, were never prescribed BP medications, and had BP measured through the 8-month visit. This mitigates the influence of changes distinct from treatment assignment across time. The change values differed significantly from placebo (P ≤.01) at month 6 (only) for both pravastatin and simvastatin. Standard errors for pravastatin: month 1, 0.98; month 6, 0.96; month 8, 1.0. Standard errors for simvastatin: month 1, 0.97; month 6, 0.98; month 8, 1.0. P values for pravastatin: month 1, P = .06; month 6, P = .004; month 8, P = .06. P values for simvastatin: month 1, P = .46; month 6, P = .01; month 8, P = .66.